Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Moderna reported its financial results for the fourth quarter and the full year of 2024, revealing both opportunities and challenges.</li><li>The company recorded total revenue of $3.2 billion for the year, a 53% decrease from 2023, attributed largely to declining product sales.</li><li>The net loss for 2024 was $3.6 billion, a slight improvement from a $4.7 billion net loss in 2023.</li></ul>

Moderna reported its financial results for the fourth quarter and the full year of 2024, revealing both opportunities and challenges.The company recorded total revenue of $3.2 billion for the year, a 53% decrease from 2023, attributed largely to declining product sales.The net loss for 2024 was $3.6 billion, a slight improvement from a $4.7 billion net loss in 2023.

Moderna Inc.: Is Its mRNA Platform Fueling A Multi-Billion-Dollar Pipeline Beyond COVID?

<ul><li>Moderna, Inc. is undergoing a profound transformation as it navigates a post-pandemic landscape marked by mounting caution among investors.</li><li>After delivering record-breaking Covid-19 vaccine sales that propelled it into the spotlight during global crisis years, the biotech giant now faces significant headwinds.</li><li>Recent updates in financial performance and strategic repositioning have underscored a shift in outlook.</li></ul>

Moderna, Inc. is undergoing a profound transformation as it navigates a post-pandemic landscape marked by mounting caution among investors.After delivering record-breaking Covid-19 vaccine sales that propelled it into the spotlight during global crisis years, the biotech giant now faces significant headwinds.Recent updates in financial performance and strategic repositioning have underscored a shift in outlook.

Moderna In Crisis? A Possible Wake-Up Call That Investors Have Been Dreading!

<ul><li>Moderna, Inc. reported its financial results for the third quarter of 2024, highlighting key developments and challenges in its business operations.</li><li>The company delivered $1.9 billion in revenue, with a net income of $13 million, and ended the quarter with $9.2 billion in cash and investments.</li><li>This financial position underscores Moderna's robust liquidity, providing it with a solid foundation to support ongoing and future initiatives.</li></ul>

Moderna, Inc. reported its financial results for the third quarter of 2024, highlighting key developments and challenges in its business operations.The company delivered $1.9 billion in revenue, with a net income of $13 million, and ended the quarter with $9.2 billion in cash and investments.This financial position underscores Moderna's robust liquidity, providing it with a solid foundation to support ongoing and future initiatives.

Moderna Inc.: Expanding Global Presence For Unmatched Impact! - Major Drivers

<ul><li>Moderna reported its Quarterly Earnings recently and managed a decent performance.</li><li>Positives from the quarter included advancements in Moderna's respiratory vaccine portfolio, particularly with mRNA-1273, its COVID-19 vaccine, and new RSV vaccine, mRESVIA.</li><li>Notably, mRNA-1273 continues to be a significant product in combating COVID-19 with substantial hospitalization rates reported from the CDC for the '23/'24 season.</li></ul>

Moderna reported its Quarterly Earnings recently and managed a decent performance.Positives from the quarter included advancements in Moderna's respiratory vaccine portfolio, particularly with mRNA-1273, its COVID-19 vaccine, and new RSV vaccine, mRESVIA.Notably, mRNA-1273 continues to be a significant product in combating COVID-19 with substantial hospitalization rates reported from the CDC for the '23/'24 season.

Moderna Inc.: These Are The 4 Biggest Challenges That Bears Are Counting On! - Major Drivers

<ul><li>Moderna Inc.'s first quarter 2024 financial results and business updates indicate a positive forward motion in the development of its business and vaccines.</li><li>The company's COVID vaccines have impacted hundreds of millions of people and through ongoing Phase III studies, Moderna expects its vaccinations to impact many more.</li><li>In the first quarter, the company made substantial clinical progress with data presentation on Epstein-Barr virus (EBV), Varicella Zoster Virus (VZV), and Norovirus.</li></ul>

Moderna Inc.'s first quarter 2024 financial results and business updates indicate a positive forward motion in the development of its business and vaccines.The company's COVID vaccines have impacted hundreds of millions of people and through ongoing Phase III studies, Moderna expects its vaccinations to impact many more.In the first quarter, the company made substantial clinical progress with data presentation on Epstein-Barr virus (EBV), Varicella Zoster Virus (VZV), and Norovirus.

Moderna Inc.: Progress in Personalized Cancer Vaccine (PCV) Manufacturing & Other Major Developments

United States

Moderna, Inc. operates as a biotechnology company. The Company focuses on the discovery and development of messenger RNA therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Moderna (MRNA US)

Moderna Inc.: Is Its mRNA Platform Fueling A Multi-Billion-Dollar Pipeline Beyond COVID?

Moderna reported its financial results for the fourth quarter and the full year of 2024, revealing both opportunities and challenges. The company...

Baptista Research

Moderna In Crisis? A Possible Wake-Up Call That Investors Have Been Dreading!

Moderna, Inc. is undergoing a profound transformation as it navigates a post-pandemic landscape marked by mounting caution among investors. After...

Baptista Research

Moderna Inc.: Expanding Global Presence For Unmatched Impact! - Major Drivers

Moderna, Inc. reported its financial results for the third quarter of 2024, highlighting key developments and challenges in its business...

Baptista Research

Moderna Inc.: These Are The 4 Biggest Challenges That Bears Are Counting On! - Major Drivers

Moderna reported its Quarterly Earnings recently and managed a decent performance. Positives from the quarter included advancements in Moderna's...

Baptista Research

Moderna Inc.: Progress in Personalized Cancer Vaccine (PCV) Manufacturing & Other Major Developments

Moderna Inc.'s first quarter 2024 financial results and business updates indicate a positive forward motion in the development of its business and...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)